Arthritis News: Breaking Arthritis News, Comments and Articles. - Page: 2

Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer

WOBURN, Mass., May 20, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc. today announced the addition of Frederick W. Driscoll to its management team as chief financial officer. Mr. Driscoll has more than 30 years of financial management experience with biotechnology and medical device companies. Prior to joining Flexion, Mr. Driscoll was chief financial officer for Novavax (NASDAQ: NVAX) wher...

Cord Blood America, Inc. Announces New Service Offering

SALT LAKE CITY, May 20, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced the launch of a new service offering for the storage of mesenchymal cells through its wholly owned subsidiary CorCell Companies, Inc. (CorCell). For additional information on the new service offering please visit our cord tissue web...

Immune protein could stop diabetes in its tracks, discovery suggests

Researchers have identified an immune protein that has the potential to stop or reverse the development of type 1 diabetes in its early stages, before insulin-producing cells have been destroyed. The discovery has wider repercussions, as the protein...

Type 1 Diabetes May Be Reversible With Immune Suppressor Protein

A professor in Melbourne, Australia, who is on a mission to find a cure for type 1 diabetes, believes that the answer, or part of it, lies with an immune suppressor protein called CD52. And if it works for type 1 diabetes, then it may well work fo...

Improving the Prognosis and Treatment of Osteoarthritis with Quantitative MRI

A new project’s goal is to assess multiple imaging and biochemical biomarkers to find more comprehensive ways to evaluate...

Joint replacement surgery might be avoidable in the future, suggest scientists

Scientists at Johns Hopkins have turned their view of osteoarthritis inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, they now have evidence that the bone undernea...

Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis

PALO ALTO, Calif., May 17, 2013 /PRNewswire/ -- Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has achieved 50% enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA). To date the trial...

Handmade Magnetic Bracelets with Gemstones Announced by Pain Free Living

Portsmouth, New Hampshire (PRWEB) May 20, 2013 Pain Free Living web: SuperiorMagnetics.com, a leader in innovative pain relief products is excited to release a line of magnetic bracelets with gemstones for arthritis pain relief. These magnetic h...

Family history may increase susceptibility to bunions

Men and women with a family history of bunions (hallux valgus) may be more likely to develop the condition themselves, a new study suggests.Researchers at Harvard Medical School in the US studied data on 1,370 people with an average age of 66 years who took part in the Framingham Foot Study.Participants underwent foot examinations to see whether they had bunions, lesser toe deformities such as ham...

Patients with severe pain likely to benefit most from joint replacement

People with severe pain and a single affected joint are likely to benefit most from hip or knee replacement surgery, new research suggests.Scientists at the University of Toronto in Canada conducted a study to determine which patients are most likely to benefit from joint replacement surgery.They looked at 202 patients, four-fifths of whom were women, with an average age of 71 years.Of these, appr...

AB Science : Launch of a Phase 3 Clinical Trial in Alzheimer's Disease

PARIS -- (Marketwired) -- 05/20/13 -- Launch of a phase 3 clinical trial in the treatment of Alzheimer's disease with masitinib First patients recruited in this study AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the launch of a phase 3 clinical trial in the treatment...

Blame your parents for bunion woes

(Wiley) A novel study reports that white men and women of European descent inherit common foot disorders, such as bunions (hallux valgus) and lesser toe deformities, including hammer or claw toe. Findings from the Framingham Foot Study -- the first t...

Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis

Osteoarthritis has been believed to be caused by improper mechanical function of articular joints. Xu Cao and his colleagues now show that this mechanical process leads to upregulation of transforming growth factor β1 activity in mesenchymal stem ce...

New theory on genesis of osteoarthritis comes with successful therapy in mice

(Johns Hopkins Medicine) Scientists at Johns Hopkins have turned their view of osteoarthritis inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, they now have eviden...

Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome

The personal injury law firm of d’Oliveira & Associates has issued an infographic on Stevens Johnson Syndrome, which details potential causes and serious conditions that may result from the syndrome. (PRWEB) May 18, 2013 According to the the Stevens Johnson Syndrome Foundation, Stevens Johnson Syndrome (SJS), also known as Toxic Epidermal Necrolysis, is a severe allergic reaction usually to...

BIBA fever as Blackpool firm wins three finalist places

An SMO business has reached the final shortlist in Lancashire’s premier business awards.MAC Clinical Research, based in the Bispham area of Blackpool, have been finalised in a hat-trick of categories including Creative Business, E-Business and...

[RuiYi] enlists the help of [Genor] to develop its RA candidate in China

[RuiYi Inc.] (formerly Anaphore) has signed on fellow antibody firm [Genor Biopharma Co. Ltd.] to help develop and exclusively commercialize in China its preclinical anti-interleukin-6 (IL-6) monoclonal antibody RYI008 for rheumatoid arthritis.

Galapagos creates new warrant plan

Mechelen, Belgium; 17 May 2013 - Galapagos NV (Euronext: GLPG) announced today that its Board of Directors created 648,490 warrants under a new warrant plan for the benefit of employees, directors and independent consultants of the Company and its subsidiaries. On 16 May 2013, the Board of Directors of Galapagos approved the "Warrant Plan 2013" within the framework of the author...

Janssen’s ulcerative colitis drug approved by US FDA

Janssen Biotech, one of Johnson & Johnson's pharma companies, has announced the FDA approval of its ulcerative colitis drug, Simponi for use in the US. The FDA has approved Simponi (golimumab) for the treatment of moderately to severely active ul...

Neovacs moving forward in rheumatoid arthritis, say analysts

French biotech firm Neovacs (Alternext Paris: ALNEV) intends to initiate a Phase IIb trial with its lead product TNFalpha-Kinoid in rheumatoid arthritis (RA). The strategy is designed to maintain momentum of the programme while it seeks a partner.

FDA approves Novartis juvenile arthritis drug

The FDA has approved Novartis’ drug Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two years and older. Ilaris is the first interleukin-1 beta (IL-1 beta) inhibitor approved for SJIA...

Edison Investment - Neovacs - Moving forward in rheumatoid arthritis

Neovacs intends to initiate a Phase IIb trial with its lead product TNFα-Kinoid in rheumatoid arthritis (RA). The strategy is designed to maintain momentum of the programme while it seeks a partner. The Kinoid approach has potentially significant commercial advantages versus existing anti-TNF products in this large, but highly competitive therapeutic area. The ability to partner this drug,...

Galapagos business update

Mechelen, Belgium; 17 May 2013 - Galapagos NV (Euronext: GLPG) announced today that the operational and financial results achieved thus far in 2013 encourage the Company to retain full year 2013 Group revenues guidance of €160 million. "Galapagos has a maturing and broad pipeline of novel mode of action programs.  Our flagship program, GLPG0634, will start a large Phase 2b study next mon...

Belgium's Galapagos says on track to meet 2013 guidance

BRUSSELS, May 17 (Reuters) - Galapagos, the Belgian developer of drugs to fight autoimmune diseases such as lupus and rheumatoid arthritis, said it was on track to meet its full-year revenue guidance this year.

Research reveals vitamin C does not reduce urate levels in gout patients

Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients with established gout. Vitami...